Monday, December 03, 2012 9:01:55 PM
$EKNL is on the edge of a HUGE breakout that can see prices soaring to multi-dollar land with KEY updates the company is expected to release from their marketing efforts from the recent Medical Conference in London – December is typically the best market gainer month if looking at the average returns over 40 years.
Interesting enough, the chart below shows the market indices performance by month with December booking the highest return month – these stocks made up primarily of large cap stocks but have a direct correlation impact on the penny stock market. With solid long term plays like EKNL, investors will definitely feel the December effect just as DROP did in 2011 reaching our $1.25 target bang on! With key breakout news ready to be unleashed, and super thin stock inventory, EKNL is primed for the biggest month on record!
The key to MEGA gains for EKNL in December is breakout trigger news and EKNL already hinted several times what the possible news can be – and we definitely expect it at any time!
We already got confirmation that the company met with key groups to finalize several deals and we expect these deals to be announced very soon.
“In addition to the hundreds of attendees who will be introduced to NCI products, NCI will be providing demonstrations to a number of parties who have expressed serious interest in FREMS and are attending to finalize purchasing arrangements” http://finance.yahoo.com/news/eko-international-corp-nerovasc-clinical-150600594.html
This is definitely a very strong statement by the company to make, and making it is a solid hint that several Major contracts are practically done and ready to be unleashed. We are on HIGH ALERT for an update on these major contacts.
Definitely we can see additional major relationships following already announced agreement with iMD Network giving EKNL direct access to thousands of doctors for referrals of Diabetic patients with Neuropathy and the need of their FREMS equipment. Additionally, their NC Stat DPN testing devices are already in over 100 Walmart stores.
No doubt, if the NC Stat device is already in one store chain, the possibility of more Walmart stores and other chain to follow is pretty good. Not to mention, the company alluded to announcing which Walmart stores already deploy the NC Stat testing devices.
The Company will shortly be providing information on locations, including the WalMart pharmacies, where testing facilities are available for patients suffering from DPN.
EKNL also announced launching of clinics for their FREMS Technology including the Mayer Institute and their first of many clinics to be opened in the USA – this is a HUGE step forward for EKNL. Not only do they have a big presence in Canada, and even teaming up with 100 Walmart stores with the NC Stat Testing device, they just announced tapping into the US market which is absolutely HUGE.
EKO INTERNATIONAL INC. (the “Company”) – (EKNL) is pleased to announce that marketing efforts initiated prior to the Canadian Federation of Podiatric Medicine Conference held in London, Ontario on October 26th and 27th, 2012, have resulted in the preparation of clinical facilities in Chicago Illinois and Sault Ste. Marie, Ontario, Canada by health professionals to administer tests and to provide treatments for diabetic patients suffering from peripheral neuropathy.
No doubt, we can see a series of updates announcing more and more clinics being launched adding the base to increase their $$ bottom lines substantially.
EKNL already provided us with an update that the company is planning for uplisting and with MaloneBailey LLP, Certified Public Accounting Firm as auditors of the Company and the share buyback program already in place we can definitely see updates on their progress – Nasdaq bound listing may very well be close at hand.
And, No doubt with the share buyback program in effect, we are definitely keeping a very close eye on the active float of 5.5 million shares and expected reduction in this number.
There is one thing for sure, we expect significant news from EKNL and “No doubt” will see a flurry of update very soon. With $2 near term price target in sights, investors stand to more than triple gains at current trading levels which closed today at $0.50 and holding solid to over 1,200% gains for over 2 months since our initial alert at $0.04. Shares are in super strong hands definitely holding well into multi-dollar levels.
Key points that make EKNL an XTREME breakout play:
1) No dilution or insiders selling any time soon and especially at these super low prices.
2) Share buyback in effect. Definitely the reason here is to move prices up to proper valuations and big boards like Nasdaq requirements. We also got confirmation with recent announcement selecting MaloneBailey LLP, Certified Public Accounting Firm as auditors of the Company.
3) Super Low float. With only 5.5 Million active float (shares available at the DTC for trading), EKNL‘s share inventory is drying up super fast, and this is already triggering a MAJOR BULLISH BREAKOUT. We expect this number to significantly reduce as the company begins their buyback program.
Interesting enough, the chart below shows the market indices performance by month with December booking the highest return month – these stocks made up primarily of large cap stocks but have a direct correlation impact on the penny stock market. With solid long term plays like EKNL, investors will definitely feel the December effect just as DROP did in 2011 reaching our $1.25 target bang on! With key breakout news ready to be unleashed, and super thin stock inventory, EKNL is primed for the biggest month on record!
The key to MEGA gains for EKNL in December is breakout trigger news and EKNL already hinted several times what the possible news can be – and we definitely expect it at any time!
We already got confirmation that the company met with key groups to finalize several deals and we expect these deals to be announced very soon.
“In addition to the hundreds of attendees who will be introduced to NCI products, NCI will be providing demonstrations to a number of parties who have expressed serious interest in FREMS and are attending to finalize purchasing arrangements” http://finance.yahoo.com/news/eko-international-corp-nerovasc-clinical-150600594.html
This is definitely a very strong statement by the company to make, and making it is a solid hint that several Major contracts are practically done and ready to be unleashed. We are on HIGH ALERT for an update on these major contacts.
Definitely we can see additional major relationships following already announced agreement with iMD Network giving EKNL direct access to thousands of doctors for referrals of Diabetic patients with Neuropathy and the need of their FREMS equipment. Additionally, their NC Stat DPN testing devices are already in over 100 Walmart stores.
No doubt, if the NC Stat device is already in one store chain, the possibility of more Walmart stores and other chain to follow is pretty good. Not to mention, the company alluded to announcing which Walmart stores already deploy the NC Stat testing devices.
The Company will shortly be providing information on locations, including the WalMart pharmacies, where testing facilities are available for patients suffering from DPN.
EKNL also announced launching of clinics for their FREMS Technology including the Mayer Institute and their first of many clinics to be opened in the USA – this is a HUGE step forward for EKNL. Not only do they have a big presence in Canada, and even teaming up with 100 Walmart stores with the NC Stat Testing device, they just announced tapping into the US market which is absolutely HUGE.
EKO INTERNATIONAL INC. (the “Company”) – (EKNL) is pleased to announce that marketing efforts initiated prior to the Canadian Federation of Podiatric Medicine Conference held in London, Ontario on October 26th and 27th, 2012, have resulted in the preparation of clinical facilities in Chicago Illinois and Sault Ste. Marie, Ontario, Canada by health professionals to administer tests and to provide treatments for diabetic patients suffering from peripheral neuropathy.
No doubt, we can see a series of updates announcing more and more clinics being launched adding the base to increase their $$ bottom lines substantially.
EKNL already provided us with an update that the company is planning for uplisting and with MaloneBailey LLP, Certified Public Accounting Firm as auditors of the Company and the share buyback program already in place we can definitely see updates on their progress – Nasdaq bound listing may very well be close at hand.
And, No doubt with the share buyback program in effect, we are definitely keeping a very close eye on the active float of 5.5 million shares and expected reduction in this number.
There is one thing for sure, we expect significant news from EKNL and “No doubt” will see a flurry of update very soon. With $2 near term price target in sights, investors stand to more than triple gains at current trading levels which closed today at $0.50 and holding solid to over 1,200% gains for over 2 months since our initial alert at $0.04. Shares are in super strong hands definitely holding well into multi-dollar levels.
Key points that make EKNL an XTREME breakout play:
1) No dilution or insiders selling any time soon and especially at these super low prices.
2) Share buyback in effect. Definitely the reason here is to move prices up to proper valuations and big boards like Nasdaq requirements. We also got confirmation with recent announcement selecting MaloneBailey LLP, Certified Public Accounting Firm as auditors of the Company.
3) Super Low float. With only 5.5 Million active float (shares available at the DTC for trading), EKNL‘s share inventory is drying up super fast, and this is already triggering a MAJOR BULLISH BREAKOUT. We expect this number to significantly reduce as the company begins their buyback program.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
